未知生产厂商
GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera. This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2). Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses.
GRAd-COV2 is a COVID-19 vaccine candidate being developed by ReiThera. This therapy is based on a novel replication-incompetent simian adenoviral vector that encodes the full-length SARS-CoV-2 spike protein (GRAd-COV2). Preclinical and clinical studies show GRAd-COV2 to induce robust cellular and humoral immune responses.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
